Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· November 27, 2025

EPR Properties EPR Q3 2025 Earnings Transcript

View original at nasdaq.com
EPR Properties EPR Q3 2025 Earnings Transcript Image source: The Motley Fool. Date Thursday, Oct. 30, 2025 at 3:46 p.m…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EPR's investment pipeline is actionable over the next 90-120 days with over $100M in committed unfunded projects

    80% confidence

  • If Genting transaction executes, it would delever EPR's balance sheet by approximately 0.3 turns

    80% confidence

  • EPR can reach target leverage without Genting proceeds or significant asset sales

    80% confidence

  • EPR has a 25-year track record navigating economic cycles and understands the importance and resilience of congregate value-oriented entertainment and leisure

    80% confidence

  • EPR projects 2026 investment spending acceleration in the $400M-$500M range

    80% confidence

  • Small bespoke relationship deals ($25M-$75M) are yielding comfortably in the 8s with less competition

    80% confidence

  • Full year 2025 box office is forecast at $9.0B-$9.2B, up approximately 6% at midpoint versus 2024

    80% confidence

  • Three Q4 2025 films (Zootopia 2, Wicked: For Good, Avatar: Fire & Ash) are each projected to exceed $200M in box office

    80% confidence

  • Genting intends to complete bond transaction and option exercise with EPR in 2026

    80% confidence

  • Percentage rent was $7M in Q3 2025 versus $5.9M in prior year, representing a key income growth driver

    80% confidence

  • The Genting transaction was never a requirement for EPR's 2026 growth plan

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com